loading...| Preferred Name |
cetuximab |
|
| Synonyms |
Chimeric Monoclonal Antibody C225 |
|
| Definitions |
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1723" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1723" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042384 |
|
| altLabel |
Chimeric Monoclonal Antibody C225 cetuximab biosimilar CDP-1 cetuximab biosimilar CMAB009 Anti-EGFR Monoclonal Antibody Chimeric MoAb C225 Anti-Epidermal Growth Factor Receptor Monoclonal Antibody cetuximab biosimilar KL 140 Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer Erbitux IMC-C225 MOAB C225 C225 monoclonal antibody C225 C225 monoclonal antibody Chimeric Anti-EGFR Monoclonal Antibody |
|
| CAS Registry |
205923-56-4 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000445429 http://purl.bioontology.org/ontology/PDQ/CDR0000385553 http://purl.bioontology.org/ontology/PDQ/CDR0000445426 http://purl.bioontology.org/ontology/PDQ/CDR0000410879 http://purl.bioontology.org/ontology/PDQ/CDR0000256467 http://purl.bioontology.org/ontology/PDQ/CDR0000373863 http://purl.bioontology.org/ontology/PDQ/CDR0000331865 http://purl.bioontology.org/ontology/PDQ/CDR0000037902 http://purl.bioontology.org/ontology/PDQ/CDR0000351778 http://purl.bioontology.org/ontology/PDQ/CDR0000368454 http://purl.bioontology.org/ontology/PDQ/CDR0000037919 http://purl.bioontology.org/ontology/PDQ/CDR0000042388 http://purl.bioontology.org/ontology/PDQ/CDR0000285685 http://purl.bioontology.org/ontology/PDQ/CDR0000042386 http://purl.bioontology.org/ontology/PDQ/CDR0000407440 http://purl.bioontology.org/ontology/PDQ/CDR0000351910 http://purl.bioontology.org/ontology/PDQ/CDR0000042923 http://purl.bioontology.org/ontology/PDQ/CDR0000438667 http://purl.bioontology.org/ontology/PDQ/CDR0000445256 http://purl.bioontology.org/ontology/PDQ/CDR0000407439 http://purl.bioontology.org/ontology/PDQ/CDR0000038338 http://purl.bioontology.org/ontology/PDQ/CDR0000038504 http://purl.bioontology.org/ontology/PDQ/CDR0000409692 |
|
| cui |
C1173436 C4732955 C0995188 C4732956 C4727808 C0879636 C4522190 |
|
| Date last modified |
2018-10-19 |
|
| definition |
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1723" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1723" NCI Thesaurus) |
|
| IND Code |
11460 3610 |
|
| Legacy PDQ ID |
5638 |
|
| LT |
TRD |
|
| NCI ID |
C1723 |
|
| notation |
CDR0000042384 |
|
| NSC Code |
714692 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
cetuximab |
|
| tui |
T116 T129 T121 |